These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 12106810)

  • 1. Carmoxirole is able to reduce amisulpride-induced hyperprolactinemia without affecting its central effect.
    Marchese G; Ruiu S; Casti P; Bartholini F; Saba P; Gessa GL; Pani L
    Eur J Pharmacol; 2002 Jun; 447(1):109-14. PubMed ID: 12106810
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of the amisulpride isomers on rat prolactinemia.
    Marchese G; Ruiu S; Casti P; Saba P; Gessa GL; Pani L
    Eur J Pharmacol; 2002 Jul; 448(2-3):263-6. PubMed ID: 12144950
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Psychopharmacological profile of amisulpride: an antipsychotic drug with presynaptic D2/D3 dopamine receptor antagonist activity and limbic selectivity.
    Perrault G; Depoortere R; Morel E; Sanger DJ; Scatton B
    J Pharmacol Exp Ther; 1997 Jan; 280(1):73-82. PubMed ID: 8996184
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prolactinemia is uncoupled from central D2/D3 dopamine receptor occupancy in amisulpride treated patients.
    Bressan RA; Erlandsson K; Spencer EP; Ell PJ; Pilowsky LS
    Psychopharmacology (Berl); 2004 Sep; 175(3):367-73. PubMed ID: 14997280
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The differential effects of atypical antipsychotics on prolactin elevation are explained by their differential blood-brain disposition: a pharmacological analysis in rats.
    Kapur S; Langlois X; Vinken P; Megens AA; De Coster R; Andrews JS
    J Pharmacol Exp Ther; 2002 Sep; 302(3):1129-34. PubMed ID: 12183672
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Usefulness of bromocriptine in the treatment of amisulpride-induced hyperprolactinemia: a case report.
    Bliesener N; Yokusoglu H; Quednow BB; Klingmüller D; Kühn KU
    Pharmacopsychiatry; 2004 Jul; 37(4):189-91. PubMed ID: 15467977
    [No Abstract]   [Full Text] [Related]  

  • 7. Amisulpride: from animal pharmacology to therapeutic action.
    Scatton B; Claustre Y; Cudennec A; Oblin A; Perrault G; Sanger DJ; Schoemaker H
    Int Clin Psychopharmacol; 1997 May; 12 Suppl 2():S29-36. PubMed ID: 9218165
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interactions of drugs acting on central dopamine receptors and cholinoceptors on yawning responses in the rat induced by apomorphine, bromocriptine or physostigmine.
    Zarrindast MR; Poursoltan M
    Br J Pharmacol; 1989 Apr; 96(4):843-8. PubMed ID: 2663110
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Amisulpride-induced hyperprolactinemia is reversible following discontinuation.
    Paparrigopoulos T; Liappas J; Tzavellas E; Mourikis I; Soldatos C
    Prog Neuropsychopharmacol Biol Psychiatry; 2007 Jan; 31(1):92-6. PubMed ID: 16938372
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New hyperprolactinemia and anovulation model in common marmoset (Callithrix jacchus) and effect of cabergoline.
    Moro M; Inada Y; Kojima M; Miyata H; Komatsu H; Torii R
    Eur J Pharmacol; 1999 Feb; 368(1):57-66. PubMed ID: 10096770
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of oestradiol-induced prolactin release in a dual-cannulated ovariectomized rat model by carmoxirole, a peripherally restricted dopamine agonist.
    Brott DA; Werkheiser JL; Campbell P; Bentley P; Andersson HH; Stewart J; Huby R; Altekar M; Kinter LB
    Basic Clin Pharmacol Toxicol; 2012 Dec; 111(6):411-6. PubMed ID: 22742711
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Positron emission tomography measurement of dopamine D₂ receptor occupancy in the pituitary and cerebral cortex: relation to antipsychotic-induced hyperprolactinemia.
    Arakawa R; Okumura M; Ito H; Takano A; Takahashi H; Takano H; Maeda J; Okubo Y; Suhara T
    J Clin Psychiatry; 2010 Sep; 71(9):1131-7. PubMed ID: 20361897
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hyperprolactinemia after low dose of amisulpride.
    Kopecek M; Bares M; Svarc J; Dockery C; Horácek J
    Neuro Endocrinol Lett; 2004 Dec; 25(6):419-22. PubMed ID: 15665803
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Amisulpride-induced hyperprolactinaemia is not reversed by addition of aripiprazole.
    Paulzen M; Gründer G
    Int J Neuropsychopharmacol; 2007 Feb; 10(1):149-51. PubMed ID: 16942633
    [No Abstract]   [Full Text] [Related]  

  • 15. Differences in effects of sultopride and sulpiride on dopamine turnover in rat brain.
    Moriuchi K; Imazu Y; Yoneda H
    Neurochem Res; 1995 Jan; 20(1):95-9. PubMed ID: 7739765
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Amisulpride the 'atypical' atypical antipsychotic--comparison to haloperidol, risperidone and clozapine.
    Natesan S; Reckless GE; Barlow KB; Nobrega JN; Kapur S
    Schizophr Res; 2008 Oct; 105(1-3):224-35. PubMed ID: 18710798
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Antipsychotic-drug-induced hyperprolactinemia: physiopathology, clinical features and guidance].
    Besnard I; Auclair V; Callery G; Gabriel-Bordenave C; Roberge C
    Encephale; 2014 Feb; 40(1):86-94. PubMed ID: 23928066
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Partial agonist properties of the antipsychotics SSR181507, aripiprazole and bifeprunox at dopamine D2 receptors: G protein activation and prolactin release.
    Cosi C; Carilla-Durand E; Assié MB; Ormiere AM; Maraval M; Leduc N; Newman-Tancredi A
    Eur J Pharmacol; 2006 Mar; 535(1-3):135-44. PubMed ID: 16554049
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Suppressive effects of chronic hyperprolactinemia on penile erection and yawning following administration of apomorphine to pituitary-transplanted rats.
    Sato F; Aoki H; Nakamura K; Taguchi M; Aoki T; Yasuda N
    J Androl; 1997; 18(1):21-5. PubMed ID: 9089064
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hyperprolactinemia and possibly related development of prolactinoma during amisulpride treatment; three cases.
    Akkaya C; Kaya B; Kotan Z; Sarandol A; Ersoy C; Kirli S
    J Psychopharmacol; 2009 Aug; 23(6):723-6. PubMed ID: 18562408
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.